7-DAY TRIAL

Track executive changes that signal opportunity

New executives evaluate solutions in their first 90 days. Get alerted when key hires happen.

Executive movement tracking • Role-based intent scoring • Direct contact information

Trial includes:

✓Complete platform access

✓Executive contact database

✓Real-time Chrome & Slack alerts

Glyco Era Ag Announces New Investor, Appoints Industry Veteran Greg Fralish As Chief Business Officer

Jan 05, 2024•over 1 year ago

Position

Chief Business Officer

Company

GlycoEra AG

Greg Fralish

WädenswilBiotechnology

Description

GlycoEra AG, a pioneering company advancing a pipeline of extracellular protein degraders for the treatment of autoimmune disorders, today announced the expansion of its Series A financing with an investment from Bristol Myers Squibb . GlycoEra also announced the addition of industry veteran Greg Fralish, Ph.D, as Chief Business Officer to expand and strengthen its leadership team.

Company Information

Company

GlycoEra AG

Location

Wädenswil, Zurich, Switzerland

About

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

FundzWatch™ Score

Medium Activity

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline